187 related articles for article (PubMed ID: 11161223)
1. Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.
Cohen MH; Hirschfeld S; Flamm Honig S; Ibrahim A; Johnson JR; O'Leary JJ; White RM; Williams GA; Pazdur R
Oncologist; 2001; 6(1):4-11. PubMed ID: 11161223
[TBL] [Abstract][Full Text] [Related]
2. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
Thürlimann B; Hess D; Köberle D; Senn I; Ballabeni P; Pagani O; Perey L; Aebi S; Rochlitz C; Goldhirsch A
Breast Cancer Res Treat; 2004 Jun; 85(3):247-54. PubMed ID: 15111763
[TBL] [Abstract][Full Text] [Related]
3. Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen.
Buzdar AU
Expert Rev Anticancer Ther; 2002 Dec; 2(6):623-9. PubMed ID: 12503208
[TBL] [Abstract][Full Text] [Related]
4. Comment on "Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results" by J.-M. Nabholtz et al.
Mouridsen HT; Chaudri-Ross HA
Eur J Cancer; 2004 May; 40(7):1095-6; author reply 1097. PubMed ID: 15093587
[No Abstract] [Full Text] [Related]
5. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
[TBL] [Abstract][Full Text] [Related]
6. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of metastatic breast carcinoma].
Puglisi F; Sobrero A
Ann Ital Chir; 1999; 70(3):377-89. PubMed ID: 10466241
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Ganz PA; Cecchini RS; Julian TB; Margolese RG; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):857-65. PubMed ID: 26686960
[TBL] [Abstract][Full Text] [Related]
9. Focus on anastrozole and breast cancer.
Mokbel K
Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Smith IE; Dowsett M; Ebbs SR; Dixon JM; Skene A; Blohmer JU; Ashley SE; Francis S; Boeddinghaus I; Walsh G;
J Clin Oncol; 2005 Aug; 23(22):5108-16. PubMed ID: 15998903
[TBL] [Abstract][Full Text] [Related]
11. Topical and oral bexarotene.
Schadt CR
Dermatol Ther; 2013; 26(5):400-3. PubMed ID: 24099070
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide as effective therapy for relapsed acute promyelocytic leukemia.
Mayorga J; Richardson-Hardin C; Dicke KA
Clin J Oncol Nurs; 2002; 6(6):341-6. PubMed ID: 12434466
[TBL] [Abstract][Full Text] [Related]
13. Advances in breast oncology: the 2002 ASCO meeting.
Singh-Ranger G; Mokbel K;
Curr Med Res Opin; 2002; 18(7):401-6. PubMed ID: 12487506
[TBL] [Abstract][Full Text] [Related]
14. Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia.
Soignet SL
Oncologist; 2001; 6 Suppl 2():11-6. PubMed ID: 11331435
[TBL] [Abstract][Full Text] [Related]
15. Is low-dose tamoxifen useful for the treatment and prevention of breast cancer?
Wu K; Brown P
J Natl Cancer Inst; 2003 Jun; 95(11):766-7. PubMed ID: 12783921
[No Abstract] [Full Text] [Related]
16. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
Leu L; Mohassel L
Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of a case of relapsed acute promyelocytic leukemia with arsenic trioxide.
Hirayama Y; Koyama R; Nagai T; Ohta H; Kondo A; Ishikawa K; Ishitani K; Matsunaga T; Sakamaki S; Niitsu Y
Intern Med; 2001 Nov; 40(11):1136-9. PubMed ID: 11757771
[TBL] [Abstract][Full Text] [Related]
18. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.
Esteva FJ; Glaspy J; Baidas S; Laufman L; Hutchins L; Dickler M; Tripathy D; Cohen R; DeMichele A; Yocum RC; Osborne CK; Hayes DF; Hortobagyi GN; Winer E; Demetri GD
J Clin Oncol; 2003 Mar; 21(6):999-1006. PubMed ID: 12637463
[TBL] [Abstract][Full Text] [Related]
19. Anastrozole: in early breast cancer.
Wellington K; Faulds DM
Drugs; 2002; 62(17):2483-90; discussion 2491-2. PubMed ID: 12421108
[TBL] [Abstract][Full Text] [Related]
20. Arsenic trioxide in the treatment of relapsed and refractory acute promyelocytic leukemia.
Asou N
Intern Med; 2005 Aug; 44(8):775-6. PubMed ID: 16157968
[No Abstract] [Full Text] [Related]
[Next] [New Search]
